CytomX Therapeutics
CTMX
122 hedge funds and large institutions have $359M invested in CytomX Therapeutics in 2021 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 17 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 35
2.89% more ownership
Funds ownership: 84.31% → 87.2% (+2.9%)
3% less funds holding
Funds holding: 126 → 122 (-4)
15% less capital invested
Capital invested by funds: $422M → $359M (-$63.1M)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
62% less call options, than puts
Call options by funds: $132K | Put options by funds: $351K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$18.1M |
| 2 |
O
OrbiMed
New York
|
+$11.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.79M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.79M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$6.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$43.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.85M |
| 3 |
PA
Perceptive Advisors
New York
|
-$3.99M |
| 4 |
Renaissance Technologies
New York
|
-$3.32M |
| 5 |
Two Sigma Investments
New York
|
-$3.11M |
CTMX Hedge Fund Activity: Q2 2021 in Review
122 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2021, worth a combined $359M — down 15% from $422M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of CTMX and 14 opened new positions — a net loss of 3 holders — while 35 trimmed existing stakes and 56 added.
The largest buyer was Candriam SCA, adding an estimated $18.1M. The largest seller was BVF Inc, exiting entirely with an estimated $43.1M sold.
- 122 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2021, down from 126 in Q1 2021.
- Funds reported $359M of CytomX Therapeutics stock for Q2 2021, down 15% quarter-over-quarter.
- 14 funds opened new CytomX Therapeutics positions in Q2 2021 and 17 closed out, a net change of -3 holders.
- The largest CytomX Therapeutics buyer in Q2 2021 was Candriam SCA, an estimated $18.1M added.
- The largest CytomX Therapeutics seller in Q2 2021 was BVF Inc, an estimated $43.1M sold.
Based on aggregated 13F filings for Q2 2021.